Skip to main content

Universal Flu Vaccine

Objective

Currently licensed influenza vaccines promote an effective antibody response, but only against influenza virus strains that antigenically match the vaccine composition. Little protection is induced by these vaccines against antigenically drifted strains such as those emerging from an avian or swine reservoir. Hence there is a great need to develop broadly cross-reactive flu-vaccines.
The aim is to establish a European training platform to integrate young researchers in a highly innovative interdisciplinary strategy to develop mucosal flu-vaccines. The Universal Influenza Vaccine (UNIFLUVAC) network is aimed at harnessing the expertise of the most accomplished vaccine researchers, developers and regulators in Europe in a timely and multidisciplinary training approach unparalleled in any single EU country. The training program is extensive and builds on the integrated added values of complementing expertise and the full access to state-of-the- art technologies and excellent training environments. This unique consortium has 2 SMEs as fully committed members to guarantee strong intersectoral cooperation between industry and academia.

The partners represent 6 leading universities in 6 different member countries, securing excellent presence in Europe. The structure of UNIFLUVAC is specifically adapted to operate over the whole range of specialized expertise needed. Specifically, UNIFLUVAC provides vaccine antigen identification and expression, adjuvant design and formulation, testing in state-of-the-art preclinical animal models and finally clinical safety, immunogenicity and efficacy trials in excellent and for Europe unique medical centres. This is the strength and appeal of the UNIFLUVAC proposal. It will also establish a long-term European network based on a new cohort of young professionals with excellent employability and career opportunities in academic, clinical or industrial settings. UNIFLUVAC will have a major impact on human health in Europe and globally.

Field of science

  • /medical and health sciences/health sciences/infectious disease/RNA virus/influenza
  • /medical and health sciences/basic medicine/pharmacology and pharmacy/pharmaceutical drug/vaccines

Call for proposal

FP7-PEOPLE-2013-ITN
See other projects for this call

Funding Scheme

MC-ITN - Networks for Initial Training (ITN)
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

GOETEBORGS UNIVERSITET
Address
Vasaparken
405 30 Goeteborg
Sweden
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 274 931,18
Administrative Contact
Henrik Lindskog (Dr.)

Participants (7)

KING'S COLLEGE LONDON
United Kingdom
EU contribution
€ 915 316,16
Address
Strand
WC2R 2LS London
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Paul Labbett (Mr.)
VIB VZW
Belgium
EU contribution
€ 589 160
Address
Rijvisschestraat 120
9052 Zwijnaarde - Gent
Activity type
Research Organisations
Administrative Contact
Rik Audenaert (Mr.)
UNIVERSITAETSKLINIKUM FREIBURG
Germany
EU contribution
€ 165 218,90
Address
Hugstetter Strasse 49
79106 Freiburg
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Juergen Dreyer (Mr.)
UNIVERSITE DE LILLE II - DROIT ET SANTE
France
EU contribution
€ 430 981,11
Address
Rue Paul Duez 42
59800 Lille
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Marie Gompel (Dr.)
ISTITUTO EUROPEO DI ONCOLOGIA SRL
Italy
EU contribution
€ 387 926,77
Address
Via Filodrammatici 10
20121 Milano
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Ilaria Foti (Ms.)
RETROSCREEN VIROLOGY LTD

Participation ended

United Kingdom
Address
New Road Queen Mary Bioenterprise Innovation Centre 42
E1 2AX London
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Paul Cooper (Mr.)
MIVAC DEVELOPMENT AB
Sweden
EU contribution
€ 353 166,88
Address
Arvid Wallgrens Backe 20
413 46 Goteborg
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Elisabeth Litsmark Nordenstam (Mrs.)